Globus医疗 GMED 深 沪
已收盘 01-30 16:00:00 美东时间
90.68
+0.460
+0.51%
华盛通- 最 高93.63
- 今 开91.75
- 成交量 106.31万股
- 最 低 89.66
- 昨 收 90.22
- 总市值 121.51亿
- 52周最高 101.3975
- 市盈率 静 121.39
- 换手率 0.79%
- 52周最低 51.79
- 委 比 33.77%
- 总股本 1.34亿
- 历史最高 101.3975
- 量 比 1.00
- 振 幅 4.40%
- 历史最低 10.26
- 每 手 1
- 风险率 13.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Needham Upgrades Globus Medical to Buy, Announces $112 Price Target
Needham analyst David Saxon upgrades Globus Medical (NYSE:GMED) from Hold to Buy and announces $112 price target.
01-30 19:49
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings Jan 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMETEK, Stryker and Zimmer Biomet Holdings, on Tuesday. HIGHLIGHTS * AMETEK AME.N : Oppenheimer cuts to
01-27 15:49
Zimmer Biomet drops after cautious remarks on outlook
Zimmer Biomet (ZBH) shares reached a session low on Tuesday as the company issued cautious remarks on its outlook during its presentation at the ongoing J.P. Morgan Healthcare Conference in San Franci...
01-14 02:13
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Biggest stock movers Thursday: Defense stocks, and more
Stock futures dipped modestly in early Thursday trade, as market participants braced for key U.S. employment data later in the week and weighed persistent geopolitical tensions. Here are some of Thurs...
01-08 18:01
Globus Medical shares are trading higher after the company reported preliminary Q4 and FY26 results.
Globus Medical shares are trading higher after the company reported preliminary...
01-08 05:32
